欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日韩亚洲一区在线 | 欧美日韩中文字幕在线一区二区 | 亚洲精品91 | 日韩精品一区二区三 | 国产男女激烈在线观看无遮挡 | 白嫩白嫩bbwbbwbbw | 亚洲无码偷拍福利 | 欧美日韩另类在线专区卡通 | 亚洲综合亚洲综合网成人 | 欧美激情视频一区 | 国产人成亚 | a在线观看 | 好硬好紧好湿进去了好爽 | 欧美又大粗又爽又黄大片视频 | 91免费网址 | 国产综合 | 久久成年片色大黄全免费网站 | 成年禁止18网站永久入口 | a级日韩乱理伦片 | 91免费看`日韩一区二区 | 成人小视频在 | 人妖视频日本一 | 国产乱码精品一 | 中文字幕乱视频在线观看 | 免费国产精品视频 | 久久久国产精品无码免费专区 | 亚洲欧洲精品成人久久曰影片 | 国产精品大神在线播放 | 亚洲国内精品自在自线国产精品 | 在线亚洲欧 | 嗯啊国产视频 | 国产av高清无亚洲 | 久久精品高清一区二区三区 | 国产成a人亚洲精v品无码樱花 | 伦精品视频 | 综合国产精品2025 | 99久久婷 | 一级a一级a爰片免费啪啪女女 | 国产在线国偷精品产拍 | 日韩精品一区二区三区视频网 | 91成人无|